Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Prelude Therapeutics Incorporated (PRLD) had Stock-Based Compensation of $5.55M for the most recently reported fiscal quarter, ending 2024-03-31.
| Income Statement Financials | |
-- |
|
$-31.43M |
|
-- |
|
-- |
|
$34.34M |
|
$-34.34M |
|
$2.91M |
|
$-31.43M |
|
$-31.43M |
|
$-31.43M |
|
$-31.43M |
|
$-31.43M |
|
$-31.43M |
|
$-34.34M |
|
$-35.46M |
|
75.74M |
|
75.74M |
|
$-0.42 |
|
$-0.42 |
|
| Balance Sheet Financials | |
$205.37M |
|
$7.29M |
|
$41.74M |
|
$247.11M |
|
$17.64M |
|
-- |
|
$18.73M |
|
$36.37M |
|
$210.73M |
|
$210.73M |
|
$210.73M |
|
54.92M |
|
| Cash Flow Statement Financials | |
$-31.79M |
|
$31.22M |
|
$-0.01M |
|
$29.34M |
|
$28.75M |
|
$-0.58M |
|
|
Stock-Based Compensation |
$5.55M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
11.64 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-32.08M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-14.91% |
|
-14.91% |
|
-12.72% |
|
-14.91% |
|
$3.84 |
|
$-0.42 |
|
$-0.42 |
|